Pay in 4 interest-free payments of $6.27 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
This evidence-based personalization accelerates efficacy, improves side effect tolerance through informed dose timing, and optimizes overall treatment outcomes
The transcription regulator, forkhead box class O isoforms 4 (FOXO4), maintains the viability of senescent cells by localizing adjacent to p53-pS15 to prevent the nuclear exclusion of active p53-pS15 to mediate apoptosis 11
Dual RNA-seq of Mtb-infected macrophages in vivo reveals ontologically distinct host-pathogen interactions
The main factors that increase risk include a sensitive gut, quick dose increases, existing digestive conditions, medication interactions, certain foods, and dehydration
57:101865 [PMC free article: PMC9981899] [PubMed: 36874396] 348
In 2025, the company reported a solid +8.62% YoY revenue growth, supported by its oncology franchise: Tagrisso ($7.25B) continues to lead in lung cancer with strong global adoption, Imfinzi ($6.06B) is expanding across multiple cancer indications, and Calquence ($3.51B) is gaining traction in hematologic cancers - reflecting sustained momentum in its cancer portfolio
